logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer To Report Phase III EINSTEIN-PE Results In Late-BreakingTrials At ACC 2012

Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the Phase III EINSTEIN-PE study, with nearly 5,000 patients, would be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 - 09:30am CDT, at the American College of Cardiology's 61st Annual Scientific Sessions or ACC in Chicago, USA, by lead investigator Harry Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.

The EINSTEIN-PE study compared an oral single-drug approach with rivaroxaban, intensified initial treatment with rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily, with the current standard of care of initial subcutaneous enoxaparin followed by a VKA in patients with acute symptomatic pulmonary embolism or PE with or without symptomatic deep vein thrombosis or DVT.

This multinational, randomized, event-driven trial with blinded outcome assessment was sponsored by Bayer HealthCare and Janssen Research & Development, LLC.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. said Tuesday after the markets closed that its first quarter profit rose 38% from last year, driven by all time record revenue from iPhone and Mac sales as well as record performance of its App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales. We are just a few weeks into 2015 and it has already been a busy year for merger deals and merger talks. Here is a list of some of the M&A stories that have made headlines so far in 2015. Diversified electronics maker TE Connectivity Ltd. is nearing a deal to sell its network solutions business unit to CommScope Holding Co., Inc. (COMM) in a deal valued at about $3 billion, according a Wall Street Journal report on Monday. A deal could be announced as early as this week. There has...
comments powered by Disqus
Follow RTT